Colorectal Cancer Cell Invasion and Functional Properties Depend on Peri-Tumoral Extracellular Matrix.

3D cell cultures colorectal cancer doxorubicin epithelial-to-mesenchymal transition (EMT) matrigel matrix metalloproteinases scanning electron microscopy type I collagen

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
22 Jun 2023
Historique:
received: 24 05 2023
revised: 16 06 2023
accepted: 19 06 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

We investigated how the extracellular matrix (ECM) affects LoVo colorectal cancer cells behavior during a spatiotemporal invasion. Epithelial-to-mesenchymal transition (EMT) markers, matrix-degrading enzymes, and morphological phenotypes expressed by LoVo-S (doxorubicin-sensitive) and higher aggressive LoVo-R (doxorubicin-resistant) were evaluated in cells cultured for 3 and 24 h on Millipore filters covered by Matrigel, mimicking the basement membrane, or type I Collagen reproducing a desmoplastic lamina propria. EMT and invasiveness were investigated with RT-qPCR, Western blot, and scanning electron microscopy. As time went by, most gene expressions decreased, but in type I Collagen samples, a strong reduction and high increase in MMP-2 expression in LoVo-S and -R cells occurred, respectively. These data were confirmed by the development of an epithelial morphological phenotype in LoVo-S and invading phenotypes with invadopodia in LoVo-R cells as well as by protein-level analysis. We suggest that the duration of culturing and type of substrate influence the morphological phenotype and aggressiveness of both these cell types differently. In particular, the type I collagen meshwork, consisting of large fibrils confining inter fibrillar micropores, affects the two cell types differently. It attenuates drug-sensitive LoVo-S cell aggressiveness but improves a proteolytic invasion in drug-resistant LoVo-R cells as time goes by. Experimental studies on CRC cells should examine the peri-tumoral ECM components, as well as the dynamic physical conditions of TME, which affect the behavior and aggressiveness of both drug-sensitive and drug-resistant LoVo cells differently.

Identifiants

pubmed: 37509428
pii: biomedicines11071788
doi: 10.3390/biomedicines11071788
pmc: PMC10376217
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Prog Mol Biol Transl Sci. 2014;126:317-52
pubmed: 25081624
Nat Mater. 2023 Jan;22(1):117-127
pubmed: 36456871
BMC Cancer. 2020 Jul 15;20(1):660
pubmed: 32669083
Cells. 2020 Sep 04;9(9):
pubmed: 32899718
Diagnostics (Basel). 2021 Mar 09;11(3):
pubmed: 33803206
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Sci Rep. 2015 Nov 13;5:16538
pubmed: 26563869
Front Bioeng Biotechnol. 2020 Nov 20;8:596599
pubmed: 33330427
FEBS Lett. 2022 Mar;596(5):638-654
pubmed: 34787896
PLoS One. 2012;7(3):e33476
pubmed: 22479403
Exp Ther Med. 2018 Apr;15(4):3751-3758
pubmed: 29581735
J Hematol Oncol. 2022 Mar 24;15(1):34
pubmed: 35331296
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Bioengineering (Basel). 2023 Jan 19;10(2):
pubmed: 36829629
Int J Colorectal Dis. 2005 May;20(3):245-52
pubmed: 15592677
Eur J Med Chem. 2017 Feb 15;127:577-585
pubmed: 28109950
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Sci Rep. 2020 Aug 6;10(1):13254
pubmed: 32764590
Cell. 2013 Dec 19;155(7):1639-51
pubmed: 24332913
J Exp Clin Cancer Res. 2022 Sep 16;41(1):276
pubmed: 36114508
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
Int J Cancer. 2003 Nov 20;107(4):541-50
pubmed: 14520690
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nature. 2022 Nov;611(7935):365-373
pubmed: 36323783
FEBS J. 2021 Dec;288(24):6850-6912
pubmed: 33605520
Int J Mol Sci. 2021 Aug 31;22(17):
pubmed: 34502361
J Clin Med. 2019 Feb 07;8(2):
pubmed: 30736469
Biomolecules. 2022 Nov 30;12(12):
pubmed: 36551219
Oncol Lett. 2017 Nov;14(5):5865-5870
pubmed: 29113219
Front Mol Biosci. 2022 Apr 26;9:864302
pubmed: 35558554
Oncogene. 2018 Aug;37(35):4769-4780
pubmed: 29780167
BMC Cancer. 2021 Feb 10;21(1):149
pubmed: 33568081
Stem Cell Rev Rep. 2015 Oct;11(5):710-27
pubmed: 26085192
Gut. 2022 Sep;71(9):1843-1855
pubmed: 34921062
J Transl Med. 2019 Sep 14;17(1):309
pubmed: 31521169
Dev Dyn. 2007 Jun;236(6):1683-93
pubmed: 17440987
Cancer Cell Int. 2010 Aug 13;10:26
pubmed: 20707917
Gels. 2022 Sep 07;8(9):
pubmed: 36135279
Curr Opin Cell Biol. 2010 Oct;22(5):697-706
pubmed: 20822891
Nat Phys. 2022 Sep;18(9):1112-1121
pubmed: 37220497
Int J Mol Sci. 2018 Sep 20;19(10):
pubmed: 30241395
Am J Pathol. 2011 Mar;178(3):1221-32
pubmed: 21356373
BMC Med. 2021 Nov 18;19(1):273
pubmed: 34789257
BMC Mol Cell Biol. 2022 Jan 3;23(1):1
pubmed: 34979904
J Biol Chem. 1995 Mar 17;270(11):5872-6
pubmed: 7890717
Sci Rep. 2017 Nov 2;7(1):14956
pubmed: 29097791
Sci Adv. 2019 Jul 24;5(7):eaaw7243
pubmed: 31355337
Science. 2016 Apr 8;352(6282):167-9
pubmed: 27124449
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
Matrix Biol. 2017 Dec;64:6-16
pubmed: 28389162
Eur J Cell Biol. 2022 Apr;101(2):151220
pubmed: 35366585
Biophys J. 2014 Dec 2;107(11):2546-58
pubmed: 25468334
Front Cell Dev Biol. 2015 Feb 02;3:4
pubmed: 25699257
Br J Cancer. 2008 Jun 3;98(11):1820-3
pubmed: 18506186
Clin Cancer Res. 2015 Aug 1;21(15):3561-8
pubmed: 25695692
Transl Oncol. 2021 Jan;14(1):100899
pubmed: 33080522
Oncotarget. 2020 Sep 22;11(38):3486-3488
pubmed: 33014284

Auteurs

Marco Franchi (M)

Department for Life Quality Studies, University of Bologna, 47900 Rimini, Italy.

Konstantinos-Athanasios Karamanos (KA)

Department of Pharmacy and Industrial Pharmacy, University of Bologna, 40126 Bologna, Italy.

Concettina Cappadone (C)

Department of Pharmacy and Biotechnologies, University of Bologna, 40126 Bologna, Italy.

Natalia Calonghi (N)

Department of Pharmacy and Biotechnologies, University of Bologna, 40126 Bologna, Italy.

Nicola Greco (N)

Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy.

Leonardo Franchi (L)

Department of Medicine, University of Bologna, 40126 Bologna, Italy.

Maurizio Onisto (M)

Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy.

Valentina Masola (V)

Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy.

Classifications MeSH